Safety and efficacy of acellular human amniotic fluid and membrane in the treatment of non-healing wounds in a patient with chronic venous insufficiency.

Autor:	Ditmars FS; Department of Surgery, Transplant Division, The University of Texas Medical Branch, Galveston, TX, USA., Lind RA; Carmel Foot Specialists, Charlotte, NC, USA., Broderick TC; Merakris Therapeutics, RTP Frontier, Research Triangle Park, NC, USA., Fagg WS; Department of Surgery, Transplant Division, The University of Texas Medical Branch, Galveston, TX, USA.; Merakris Therapeutics, RTP Frontier, Research Triangle Park, NC, USA.; Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA.
Jazyk:	angličtina
Zdroj:	SAGE open medical case reports [SAGE Open Med Case Rep] 2022 May 21; Vol. 10, pp. 2050313X221100882. Date of Electronic Publication: 2022 May 21 (Print Publication: 2022).
DOI:	10.1177/2050313X221100882
Abstrakt:	Chronic, non-healing venous ulcers of the lower extremity are often limb-threatening conditions. Their management is characterized by a prolonged and frequently frustrating clinical course that represents an economic burden to both the patient and healthcare system. During the last two decades, thermal ablation of underlying incompetent venous systems has been extensively utilized to treat chronic venous insufficiency. Despite successful correction of venous hypertension, a substantial subgroup of patients remain affected by non-healing venous ulcers, thus posing a significant clinical challenge. In this case report, we detail quantitative and qualitative wound treatment course in a patient refractory to standard interventions, by treatment with a combination of cell-free amniotic fluid and dehydrated amniotic membrane following successful thermal ablation of refluxing veins. Competing Interests: Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: T.C.B. and W.S.F. are co-founders of and shareholders in Merakris Therapeutics. The products used to treat the patient in this case report were Dermacyte® Liquid and Dermacyte® Matrix, and were obtained from Merakris Therapeutics. (© The Author(s) 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu